中国中西医结合急救杂志
中國中西醫結閤急救雜誌
중국중서의결합급구잡지
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2015年
6期
565-568
,共4页
肺疾病,阻塞性,慢性%稳定期%穴位注射%健康教育%肾阳虚证%喘可治注射液
肺疾病,阻塞性,慢性%穩定期%穴位註射%健康教育%腎暘虛證%喘可治註射液
폐질병,조새성,만성%은정기%혈위주사%건강교육%신양허증%천가치주사액
Chronic obstructive pulmonary disease%Stable stage%Acupoint injection%Health education%Kidney yang deficiency syndrome%Chuankezhi injection
目的：观察慢性阻塞性肺疾病（COPD）稳定期脾肾阳虚证患者应用喘可治注射液穴位注射治疗配合护理健康教育的临床疗效。方法采用前瞻性研究方法，选择2014年2至4月在杭州市第三人民医院和浙江省新华医院诊治的118例COPD稳定期脾肾阳虚证患者，按随机数字表法分为试验组60例和对照组58例。两组患者均给予常规治疗〔按COPD全球倡议（GOLD）采用氧疗、支气管扩张剂、糖皮质激素、康复治疗〕；试验组同时穴位注射喘可治注射液，每日1次，疗程12周，并配合相应的健康教育。定期随访9个月，比较两组患者的肺功能、生活质量和预后。结果12周后，试验组1秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）、每分钟最大通气量（MVV）均显著高于对照组〔FEV1（L）为1.57±0.42比1.35±0.35，FEV1/FVC为（58.62±4.56）%比（50.36±4.35）%，MVV（L/min）为60.62±7.56比56.95±6.33，均P＜0.05〕。试验组COPD生活质量评价表（QLICD-COPD）躯体功能、心理功能、社会功能、呼吸特异模块的评分均显著高于对照组（分：总分为74.69±8.92比68.62±8.95，躯体功能为74.16±8.55比66.31±7.15，心理功能为78.69±9.79比72.64±8.45，社会功能为75.45±6.75比70.36±6.12，呼吸特异模块为67.52±6.33比61.36±6.17，均P＜0.05）；Barthel指数评分也显著高于对照组（分：75.41±9.24比68.43±7.95，P＜0.05）。随访9个月内，试验组COPD急性发作的发生率均显著低于对照组〔5.00%（3/60）比17.24%（10/58），P＜0.05〕；患者的再入院率也明显少于对照组〔1.67%（1/60）比12.07%（7/58），P＜0.05〕。结论喘可治注射液穴位注射配合健康教育对COPD稳定期脾肾阳虚证患者有良好的临床疗效，值得推广。
目的：觀察慢性阻塞性肺疾病（COPD）穩定期脾腎暘虛證患者應用喘可治註射液穴位註射治療配閤護理健康教育的臨床療效。方法採用前瞻性研究方法，選擇2014年2至4月在杭州市第三人民醫院和浙江省新華醫院診治的118例COPD穩定期脾腎暘虛證患者，按隨機數字錶法分為試驗組60例和對照組58例。兩組患者均給予常規治療〔按COPD全毬倡議（GOLD）採用氧療、支氣管擴張劑、糖皮質激素、康複治療〕；試驗組同時穴位註射喘可治註射液，每日1次，療程12週，併配閤相應的健康教育。定期隨訪9箇月，比較兩組患者的肺功能、生活質量和預後。結果12週後，試驗組1秒用力呼氣容積（FEV1）、FEV1/用力肺活量（FVC）、每分鐘最大通氣量（MVV）均顯著高于對照組〔FEV1（L）為1.57±0.42比1.35±0.35，FEV1/FVC為（58.62±4.56）%比（50.36±4.35）%，MVV（L/min）為60.62±7.56比56.95±6.33，均P＜0.05〕。試驗組COPD生活質量評價錶（QLICD-COPD）軀體功能、心理功能、社會功能、呼吸特異模塊的評分均顯著高于對照組（分：總分為74.69±8.92比68.62±8.95，軀體功能為74.16±8.55比66.31±7.15，心理功能為78.69±9.79比72.64±8.45，社會功能為75.45±6.75比70.36±6.12，呼吸特異模塊為67.52±6.33比61.36±6.17，均P＜0.05）；Barthel指數評分也顯著高于對照組（分：75.41±9.24比68.43±7.95，P＜0.05）。隨訪9箇月內，試驗組COPD急性髮作的髮生率均顯著低于對照組〔5.00%（3/60）比17.24%（10/58），P＜0.05〕；患者的再入院率也明顯少于對照組〔1.67%（1/60）比12.07%（7/58），P＜0.05〕。結論喘可治註射液穴位註射配閤健康教育對COPD穩定期脾腎暘虛證患者有良好的臨床療效，值得推廣。
목적：관찰만성조새성폐질병（COPD）은정기비신양허증환자응용천가치주사액혈위주사치료배합호리건강교육적림상료효。방법채용전첨성연구방법，선택2014년2지4월재항주시제삼인민의원화절강성신화의원진치적118례COPD은정기비신양허증환자，안수궤수자표법분위시험조60례화대조조58례。량조환자균급여상규치료〔안COPD전구창의（GOLD）채용양료、지기관확장제、당피질격소、강복치료〕；시험조동시혈위주사천가치주사액，매일1차，료정12주，병배합상응적건강교육。정기수방9개월，비교량조환자적폐공능、생활질량화예후。결과12주후，시험조1초용력호기용적（FEV1）、FEV1/용력폐활량（FVC）、매분종최대통기량（MVV）균현저고우대조조〔FEV1（L）위1.57±0.42비1.35±0.35，FEV1/FVC위（58.62±4.56）%비（50.36±4.35）%，MVV（L/min）위60.62±7.56비56.95±6.33，균P＜0.05〕。시험조COPD생활질량평개표（QLICD-COPD）구체공능、심리공능、사회공능、호흡특이모괴적평분균현저고우대조조（분：총분위74.69±8.92비68.62±8.95，구체공능위74.16±8.55비66.31±7.15，심리공능위78.69±9.79비72.64±8.45，사회공능위75.45±6.75비70.36±6.12，호흡특이모괴위67.52±6.33비61.36±6.17，균P＜0.05）；Barthel지수평분야현저고우대조조（분：75.41±9.24비68.43±7.95，P＜0.05）。수방9개월내，시험조COPD급성발작적발생솔균현저저우대조조〔5.00%（3/60）비17.24%（10/58），P＜0.05〕；환자적재입원솔야명현소우대조조〔1.67%（1/60）비12.07%（7/58），P＜0.05〕。결론천가치주사액혈위주사배합건강교육대COPD은정기비신양허증환자유량호적림상료효，치득추엄。
Objective To observe the clinical efficacy of Chuankezhi acupoint injection combined with nursing health care education for treatment of patients with chronic obstructive pulmonary disease (COPD) at stable stage complicated with spleen kidney deficiency syndrome.Methods A prospective study was conducted. 118 patients with stable COPD and spleen kidney yang deficiency syndrome admitted to Hangzhou Third People's Hospital and Zhejiang Xinhua Hospital from February to April 2014 were enrolled, and they were divided into an experimental group (60 cases) and a control group (58 cases) according to the random number table. Both groups were given conventional treatment [including oxygen therapy, bronchodilators, corticosteroids, rehabilitation therapy in accord with the Global Initiative COPD (GOLD)]. Simultaneously, in the experimental group, Chuankezhi acupoint injection was additionally given, once daily for 12 weeks, and appropriate corresponding health education was mentioned. The lung function, quality of life and prognoses of the patients were regularly followed up for 9 months and compared between the two groups.Results After 12 weeks, one second forced expiratory volume (FEV1), FEV1/forced vital capacity (FVC) and maximum voluntary ventilation (MVV) per minute in the experimental group were significantly higher than those in control group [FEV1 (L): 1.57±0.42 vs. 1.35±0.35, FEV1/FVC: (58.62±4.56)% vs. (50.36±4.35)%, MVV (L/min): 60.62±7.56 vs. 56.95±6.33, allP < 0.05]. The quality of life evaluation form for COPD (QLICD-COPD) was used to evaluate the physical function, psychological function, social function and specific modules scores, showing that the above items in the experimental group were significantly higher than those in control group (total score: 74.69±8.92 vs. 68.62±8.95, physical function score: 74.16±8.55 vs. 66.31±7.15, mental function score: 78.69±9.79 vs. 72.64±8.45, social function score: 75.45±6.75 vs. 70.36±6.12, specific modules score: 67.52±6.33 vs. 61.36±6.17, allP < 0.05); Barthel index score was also significantly higher than that in the control group (75.41±9.24 vs. 68.43±7.95,P < 0.05). Within 9 months of follow-up, the incidence of acute exacerbation of COPD in the experimental group was significantly lower than that in the control group [5.00% (3/60) vs. 17.24% (10/58),P < 0.05]. The re-admission rate was also significantly less in patients in experimental group compared with that of control group [1.67% (1/60) vs. 12.07% (7/58),P < 0.05]. Conclusion Chuankezhi acupoint injection with health education for treatment of patients with COPD at stable stage and spleen kidney yang deficiency syndrome has good clinical efficacy, worthy to be applied more widely.
